Hemangioma
32
2
2
19
Key Insights
Highlights
Success Rate
79% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
15.6%
5 terminated out of 32 trials
79.2%
-7.3% vs benchmark
16%
5 trials in Phase 3/4
37%
7 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 19 completed trials
Clinical Trials (32)
A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies
Fluctuational Imaging for the Diagnosis of Hepatic Hemangioma: A Multicenter, Prospective Study
Clinical Characteristics of Infantile Hemangioma
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
Natural Berry Extract Treatment of Hemangiomas
Topical Timolol for Superficial Infantile Hemangioma
Role of Propranolol as Compared to Bleomycin in Management of Hemangioma
Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma
Vascular Anomaly Pathology and Genomics Biopsy Study
A Prospective Longitudinal Study to Identify Biomarkers in Children With Hemangiomas
The Effectiveness of Diode Laser 980-nm in Iraqi Face Hemangioma: a Randomized Within Patients Trial
The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma
Topical Timolol for Infantile Hemangioma in Early Proliferative Phase
Corticosteroids With Placebo Versus Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH)
Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas
Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB
Topical Timolol Gel for the Treatment of Infantile Hemangiomas
Evaluation of New Biomarkers Predictive of Efficacy Betablockers in PEComa and Vascular Pediatric Tumors